- Home
- »
- Our Products
- »
Covid Care
Leading Exporter of paxista for covid trreatment from Thane.Paxista for Covid trreatment
Get Best Quote
Approx. Price: Rs 9,500 / BoxGet Latest Price
Product Brochure
PAXISTA - NIRMATRELVIR 150MG AND RITONAVIR 100MG TABLET Composition : Nirmatrelvir 150 mg + Ritonavir 100 mg tablet Description : Paxista is an investigational antiviral therapy medicine with active ingredients Nirmatrelvir 150 MG and Ritonavir 100 MG approved for emergency use. The drug is indicated for treating mild-to-moderate coronavirus disease in adults and pediatric patients (aged >12 years and weight>40 kg) testing positive for SARS-CoV-2 virus, at high risk of progression, including hospitalization or death. Ritonavir is co-administered with Nirmatrelvir as it acts as a pharmacokinetic enhancer resulting in higher systemic concentrations and a longer half-life of Nirmatrelvir, thereby supporting a twice-daily administration regimen
Product Details:
| Composition | PAXISTA - NIRMATRELVIR 150MG AND RITONAVIR 100MG TABLET Composition : Nirmatrelvir 150 mg + Ritonavi |
| Treatment | Covid Anti-viral pill |
| Country of Origin | Made in India |
| Packing Type | 3 strips |
| Item Name | Paxista |
| Prescription/Non prescription | Non prescription |
| Manufacture By | CVS pharmacy |
| Drug Name | Paxista |
| Pack Type | Box |
| Packaging Size | 60X60X60 |
PAXISTA - NIRMATRELVIR 150MG AND RITONAVIR 100MG TABLET Composition : Nirmatrelvir 150 mg + Ritonavir 100 mg tablet Description : Paxista is an investigational antiviral therapy medicine with active ingredients Nirmatrelvir 150 MG and Ritonavir 100 MG approved for emergency use. The drug is indicated for treating mild-to-moderate coronavirus disease in adults and pediatric patients (aged >12 years and weight>40 kg) testing positive for SARS-CoV-2 virus, at high risk of progression, including hospitalization or death. Ritonavir is co-administered with Nirmatrelvir as it acts as a pharmacokinetic enhancer resulting in higher systemic concentrations and a longer half-life of Nirmatrelvir, thereby supporting a twice-daily administration regimen
Request
Callback
Callback
Yes! I am Interested